Teva Pharmaceutical Industries Ltd. recently declared about the retirement plan of its President and CEO, Shlomo Yanai, to be effective in May 2012. Moreover, the company also announced Dr. Jeremy Levin, who is a former senior executive at Bristol-Myers Squibb (NYSE:BMY) to replace Mr. Yanai at that time.
BMY declined 0.09% in final trading of 2011 to settle at $35.24 and completed year 2011 with a positive performance of 33.08%.[article_latestnews_1]
Yanai is getting retired from the company after TEVA’s shares lost the most since 2006 in last year amid rising competition for its No. 1 drug, a branded multiple sclerosis medicine called Copaxone.
Yanai had no track-record of pharmaceutical but spent $6.5 billion in 2011 to acquire U.S. biotech Cephalon Inc., then later in December said that Teva may not able to meet its long-term sales target of $31 billion by 2015.
Teva Pharmaceutical Industries Ltd. (NASDAQ:TEVA) kicked off the last session at an opening price of $40.36 and gained as much as to reach $40.97 but later by the trade end stock decreased 1.15% to $40.36.
On the other hand, its trade volume of 3.45 million shares was less than average trading capacity of 5.27 million shares. The week-performance of the company after last close appeared at -2.54% while completed year 2011 with a negative performance of -21.03% and a month-performance after last trade went up at 1.89%.
The stock price volatility was 1.53% for a week and 2.21% for a month as well as price volatility’s Average True Range for 14 days was 0.93 and its beta remained 0.29.
TEVA generated revenue of $17.05 billion in the following twelve months and earned $3.02 billion. The Company showed a positive 18.09% in the net profit margin and its operating margin which remained 19.19%. Company’s annual sales growth for the past five years was 25.15%.
The liquidity measure in recent quarter results of the company was recorded 1.13 as current ratio and on the other side the debt to equity ratio was 0.36 while long-term debt to equity ratio remained 0.19. TEVA had a cash of $1.19 per share and a book value per share as $25.83 in the most recent quarter.
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!
Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. galaxystocks.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer ( http://galaxystocks.com/disclaimer) is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold galaxystocks.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (CRWE.OB) is a media-advertisement and newswire company. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period.
Disclaimer: Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Entire Disclaimer Here